Prevention of the OKT3 first-dose syndrome by reduced initial dose followed by adjusted doses based on CD3 T-lymphocyte counts in pediatric renal graft recipients

Transplant Proc. 1996 Dec;28(6):3466-7.
No abstract available

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Antigens, CD / analysis
  • CD3 Complex / analysis
  • Child
  • Creatinine / blood
  • Dose-Response Relationship, Drug
  • Fluorescent Antibody Technique, Indirect
  • Follow-Up Studies
  • Graft Rejection / immunology
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects*
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / physiology
  • Lymphocyte Count
  • Muromonab-CD3 / administration & dosage
  • Muromonab-CD3 / adverse effects*
  • Syndrome
  • T-Lymphocytes / immunology*
  • Time Factors

Substances

  • Antigens, CD
  • CD3 Complex
  • Immunosuppressive Agents
  • Muromonab-CD3
  • Creatinine